甲磺酸溴隐亭

甲磺酸溴隐亭

中文名称甲磺酸溴隐亭
中文同义词甲磺酸溴隐亭;2-溴-alpha-麦角环肽甲磺酸盐;2-溴-Α-麦角隐亭甲磺酸盐;甲黄酸溴麦角环肽;甲磺酸溴隐亭/甲黄酸溴麦角环肽;(6AR,9R)-5-溴-N-((2R,5S,10AS,10BS)-10B-羟基-5-异丁基-2-异丙基-3,6-二氧八氢-2H-恶唑[3,2-A]吡咯并[2,1-C]吡嗪-2-基)-7-甲基-4,6,6A,7,8,9-六氢吲哚并[4,3-FG]喹啉-9-甲酰胺甲磺酸盐;甲磺酸溴隐亭 USP标准品;甲磺酸溴隐亭 EP标准品
英文名称Bromocriptine mesylate
英文同义词(5'A)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)ERGOTAMAN-3',6',18-TRIONE MESYLATE;(+)-BROMOCRIPTINE MESYLATE;BROMOCRIPTINE MESYLATE;(+)-BROMOCRIPTINE METHANESULFONATE;BROMOCRIPTINE METHANESULPHONATE;BROMOCRYPTINE MESYLATE METHANESULFONATE SALT;(+)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)-ERGOTAMAN-3',6',18-TRIONE METHANESULFONATE;(+)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6'-18-trione methanesulfonate salt
CAS号22260-51-1
分子式C33H44BrN5O8S
分子量750.7
EINECS号244-881-1
相关类别医药原料药;医用原料;医药原料;医药原料;原料药;Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;PARLODEL;原料;化学试剂;试剂;试剂盒-细胞分析试剂盒;化学试剂-精细化工;Dopamine receptor;Pharmaceuticals
Mol文件22260-51-1.mol
结构式甲磺酸溴隐亭 结构式

甲磺酸溴隐亭 性质

熔点192-196° (dec)
比旋光度D20 +95° (c = 1 in methanol-methylene chloride)
储存条件2-8°C
溶解度H2O:0.8 mg/mL
形态固体
酸度系数(pKa)4.90(at 25℃)
颜色白色
旋光性 (optical activity)[α]20/D +95°, c = 1 in methanol: methylene chloride (1:1)(lit.)
Merck13,1400
BRN4115238
稳定性从购买之日起 2 年内保持稳定。 DMSO 或乙醇溶液可在 -20°C 下保存长达 3 个月
InChIKeyNOJMTMIRQRDZMT-JGYCFGIMSA-N
CAS 数据库22260-51-1(CAS DataBase Reference)

甲磺酸溴隐亭 用途与合成方法

甲磺酸溴隐亭最早由诺华公司开发,主要用于抗震颤麻痹,抑制生理性泌乳和治疗催乳激素过高引起的经前期综合征、肢端肥大症、女性不育症和亨丁顿舞蹈病。临床用于治疗帕金森病,与催乳素有关的生殖系统功能异常,如闭经、溢乳症、经前综合征、产褥期乳腺炎、纤维囊性乳腺瘤、男性阳痿或性欲减退,还可用于垂体腺瘤等。甲磺酸溴隐亭快速释放的口服制剂辅助用于Ⅱ型糖尿病的治疗,该药2009年5月获得FDA批准。本品又称溴麦亭、溴化麦角隐亭、溴克丁、麦角克碱、麦角环肽、抑乳停、甲磺酸溴隐亭,是麦角生物碱的半合成衍生物,能特异地兴奋中枢多巴胺受体,对其他受体有拮抗作用。无麦角类的收缩子宫和血管作用。可抑制PRL、LH的分泌,激活脑内新纹状体的多巴胺受体,控制震颤麻痹综合征;通过中枢或外周的作用松弛血管平滑肌,减低交感神经兴奋性,进而使血压下降,脉率不增加。适用于治疗高泌乳素血症及泌乳素瘤,或作为泌乳素瘤的术前准备或术后治疗;亦用于治疗垂体生长激素瘤、巨人症及肢端肥大症;或用于垂体促皮质素瘤及库欣(Cushing)病合并血糖升高者的治疗。可用于治疗多囊卵巢综合征,对排卵功能障碍性不孕症有效。对乳腺增生、回乳、月经紊乱、经前紧张综合征、肝性脑病、糖尿病、特发性水肿、垂体性甲亢及甲状腺功能减退症均有一定效果。

甲磺酸溴隐亭的合成路线

1)溴隐亭的合成

将α-麦角隐亭12g(20.8mmoL)和二氯甲烷120mL加入反应瓶中,搅拌溶清后依次加入5,5-二溴巴比妥酸3.69g(12.9mmoL)、33%氢溴酸的冰乙酸溶液0.2mL,控温25~30℃反应5~6h,过滤,滤液依次用1moL/L的硫代硫酸钠(30mL),5%的碳酸氢钠溶液(30mL),20%氯化钠溶液(30mL)洗涤。有机相用无水硫酸镁干燥,过滤,并加入硅胶36g浓缩将溶剂完全拉干。柱层析:流动相先为二氯甲烷,后为V(二氯甲烷)∶V(丙酮)=6∶1的混合溶液。得10.6g溴隐亭,收率78%。

2)甲磺酸溴隐亭的合成

将溴隐亭6.0g用二氯甲烷120mL溶清后加入2-丁酮200mL,控制内温20~30℃,加入甲磺酸1.14g,生成结晶型沉淀,搅拌1h。滤出固体,用2-丁酮30mL洗涤,干燥得6.13g甲磺酸溴隐亭,收率86%。

Bromocriptine mesylate 是一种有效的多巴胺 D2/D3 受体激动剂,结合多巴胺 D2 受体,pKi 为 8.05±0.2。

pKi: 8.05±0.2 (dopamine D2 receptor)

Bromocriptine stimulates [ 35 S]-GTPγS binding at D2 dopamine receptor expressed in CHO cells with pEC 50 of 8.15±0.05. Bromocriptine also is a strong inhibitor of brain nitric oxide synthase. The ergot alkaloid Bromocriptine (BKT) is found to act as a strong inhibitor of purified neuronal nitric oxide synthase (NOS) (IC 50 =10±2 μM) whereas it is poorly active towards inducible macrophage NOS (IC 50 >100 μM) . Bromocriptine is found to inhibit the activity of at least one human cytochrome P450 enzyme. Bromocriptine is a potent inhibitor of CYP3A4 with a calculated IC 50 value for the interaction of 1.69 μM.

Bromocriptine mesylate (2 mg/kg, i.p.) is administered for 7 days in groups of mice in forced swimming test (FST) and tail suspension test (TST). Bromocriptine group shows significant anti-immobility action as compared to control. When Bromocriptine administered 30 min after the last dose of 7 days MPE treatment and subjected to FST, this dopaminergic agonist produces significant and dose dependent potentiation of anti-immobility action of MPE (200 mg/kg, p.o.) as compared to MPE treatment alone. Bromocriptine treatment group shows a significant reduction of immobility time as compared to control. Bromocriptine administration after 7 days pretreatment with MPE (100 and 200 mg/kg, p.o.) shows significant and dose dependent potentiation of anti-immobility action of MPE as compared to MPE treatment alone. Intracisternal administration of Bromocriptine decreases significantly the static mechanical allodynia (SMA) score compared to that of sham (saline-injected rats) and its effect lasted for 30 min. Intraperitoneal administration of Bromocriptine induces a significant, dose dependent (0.1 mg and 1 mg/kg) decrease in pain scores in CCI-IoN group when compared to sham and its effect lasted for 6 h. The highest dose induces the highest score decrease (P<0.01). Bromocriptine effect lasts for 20 min. Intraperitoneal administration of Bromocriptine induces a significant dose dependent decrease in SMA score in CCI-IoN+6-OHDA lesioned group compared to that of sham. Its effect lasts for 6 h.

类别
有毒物质
毒性分级
中毒
急性毒性
口服-小鼠 LD50: 2502 毫克/公斤; 静脉-大鼠 LD50: 10.5 毫克/公斤
可燃性危险特性
热分解排出有毒氮氧化物,硫氧化物和溴化物烟雾
储运特性
库房通风干燥低温
灭火剂
水,干粉,二氧化碳,泡沫,沙土

安全信息

危险品标志Xn
危险类别码20/21/22
安全说明22-24/25-36
危险品运输编号UN 3077 9 / PGIII
WGK Germany3
RTECS号KE1595000
F3-10
海关编码29396900
毒性LD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes)

MSDS信息

提供商 语言
英文
更新日期产品编号产品名称CAS号包装价格
2024/04/30HY-12705A甲磺酸溴隐亭
Bromocriptine mesylate
22260-51-110mM * 1mLin DMSO273元
2024/04/30HY-12705ABromocriptine mesylate10 mg330元

甲磺酸溴隐亭 上下游产品信息

"甲磺酸溴隐亭"相关产品信息
甲磺酸培氟沙星 甲基磺酸 溴隐亭 偶氮氯磷 甲磺酸帕珠沙星 伊马替尼 三氟甲磺酸 麦角克碱 溴隐亭杂质E Ergoline-8-carboxylicacid,2-bromo-9,10-didehydro-6-methyl-,(8β)- BroMocriptineIMpurityF 溴隐亭-13C-D3 溴隐亭杂质G Ergotaman-3',6',18-trione,2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-,(2'β,5'α,8α)-(9CI) 麦角隐亭 (8S)-2-BroMoα-Ergocryptine BROMOCRIPTINEIMPURITYA(MIXTUREOFDIASTEREOMERS) 溴隐亭杂质2
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 | 评选活动 | HS海关编码 | MSDS查询 | 化工站点

Copyright © 2016-2023 ChemicalBook 版权所有  京ICP备07040585号  京公海网安备11010802032676号  

互联网增值电信业务经营许可证:京ICP证150597号  互联网药品信息服务资格证编号(京)-非经营性-2015-0073  信息系统安全等级保护备案证明(三级)  营业执照公示

根据相关法律法规和本站规定,单位或个人购买相关危险物品应取得有效的资质、资格条件。
参考《应急管理部等多部门关于加强互联网销售危险化学品安全管理的通知 (应急〔2022〕119号)》《互联网危险物品信息发布管理规定》